The evidence
LL-37 and biofilm
Bacteria growing as a biofilm are not the same therapeutic target as the same species in free suspension. Enclosed in a matrix they produce themselves, they tolerate both immune clearance and antimicrobial agents, and the concentration of antibiotic required to kill them can be orders of magnitude higher.
That gap is the reason cationic antimicrobial peptides are studied here at all. This page sets out what the published work on LL-37 reports against biofilm — and, just as carefully, where that evidence stops.
The problem
Why the same organism becomes a different target
A biofilm is not a crowd of bacteria. It is a structured community embedded in a matrix of polysaccharide, protein and extracellular DNA, attached to a surface — tissue, bone, a catheter, an implant.
Three things change at once:
- Penetration. The matrix slows the arrival of antimicrobials at the cells deepest in the structure.
- Physiology. Cells inside are often slow-growing or dormant, and most antibiotic classes act on processes that dormant cells are not performing.
- Immune tolerance. The structure impedes phagocytic clearance as well as chemical attack, so the two arms of treatment are blunted together.
The practical result is the figure quoted everywhere in this field: killing biofilm-encased cells can demand orders of magnitude more drug than killing the same organism planktonic — a difference commonly cited as approaching a thousandfold. LiteratureThat number is a general finding of the biofilm field rather than a measurement from a single study, and it is described that way here deliberately.
The mechanism of interest
What a cationic peptide does differently
MechanismLL-37 carries a net positive charge of about +6 against a bacterial surface that is anionic. The attraction is electrostatic and it does not depend on a specific molecular target, which is the structural reason resistance to this class arises differently from resistance to a conventional antibiotic: there is no single enzyme or binding site to modify.
Against biofilm specifically, the reported activity is not simply a consequence of killing the cells inside. Published work describes interference with biofilm formation at concentrations below those needed to inhibit growth in free-floating culture. An effect that appears below the growth-inhibitory concentration cannot be explained by killing alone, and that is what makes the observation interesting rather than merely encouraging.
The record
What the literature actually reports
Sub-inhibitory activity against biofilm
Activity described at concentrations below the growth-inhibitory level in free-floating culture, across a range of organisms. The organisms and the model differ from study to study, and so do the concentrations — this is a body of findings, not a single characterised property.
Synergy with a conventional antibiotic
LiteratureLL-37 has been reported to act synergistically with polymyxin B against both planktonic and biofilm cells of Escherichia coli and Pseudomonas aeruginosa. Synergy is the more practically interesting result of the two: it points at a combination rather than a replacement.
Randomised human work, in one indication
LL-37 has been examined in randomised, placebo-controlled studies in hard-to-heal venous leg ulcers, including a multicentric prospective trial. That is the extent of the controlled human record for this peptide — one wound indication, not a biofilm indication, and not an approval.
Where the evidence stops
Four honest limits
- Biofilm results are model-dependent. Static microtitre-plate biofilm, flow-cell biofilm and biofilm on an implanted device are three different experiments, and a result in one does not automatically hold in another. When comparing figures across papers, the model is part of the number.
- Host conditions are not culture conditions. Cationic peptide activity is sensitive to ionic strength and to serum components. Activity measured in dilute buffer is not a prediction of activity in tissue.
- The peptide is a protease substrate. Its own biology depends on proteolysis; in a wound environment full of proteases, so does its persistence.
- There is no approval. No jurisdiction has authorised LL-37 for any indication. It is a research compound, and the clinical work above is investigational.
Nothing on this page is medical advice, and nothing here describes a treatment. It is a summary of a research literature, written so that its limits are as visible as its findings.
Panacea lens
The problem that arrives after the pharmacology
Panacea research noteCharge cuts both ways
The +6 net charge is the reason LL-37 finds an anionic bacterial membrane. It is also the reason it finds glass, steel, tubing and filter membranes. Highly cationic peptides adsorb onto surfaces readily, and a peptide that has plated itself onto the inside of its own container has left the dose without undergoing any chemical change at all — which means a purity assay can look perfect while the delivered amount is wrong.
Panacea technologyThat is a container and process problem, not a chemistry problem, and it is the class of problem Panacea Bio Chem works on. For a peptide whose native design is to be stored inert and activated at the point of use, the presentation is not packaging around the mechanism — it is continuous with it.
The chain from synthesised peptide to cartridge, and the technologies built for each step of it, are set out on the main resource.
Questions
Frequently asked
Why is biofilm harder to treat than free-floating bacteria?
Three reasons compound: the matrix impedes penetration, the cells inside are often slow-growing and therefore poor targets for antibiotics that act on growth, and the structure blunts phagocytic clearance as well. The required concentration can be orders of magnitude higher than for the same organism in suspension.
Does LL-37 disrupt established biofilm, or only prevent it forming?
Published work reports both, at concentrations below those inhibiting growth in free-floating culture. Treat those as findings in specific model systems rather than a general property of the molecule — biofilm work is unusually sensitive to the model used.
How does LL-37 compare with a conventional antibiotic?
The most useful published comparison is not a contest but a combination: synergy with polymyxin B against both planktonic and biofilm cells of E. coli and P. aeruginosa. A peptide that lowers the effective dose of an established agent is a more tractable proposition than one asked to replace it.
Is LL-37 approved to treat biofilm infection?
No, and not for anything else either. There is no marketing authorisation for LL-37 in any jurisdiction. The randomised work that exists is in hard-to-heal venous leg ulcers and is investigational. Nothing here is medical advice.
What is the best way to read a biofilm paper?
Check the model before the number. Static plate, flow cell or device-associated biofilm are different experiments; the organism, the medium and the ionic strength all move the result. A concentration quoted without its model is not yet a comparable figure.
Continue